$MLYS

2 stories mentioning MLYSUpdated 38d ago

Every FINWIRES story that references MLYS, newest first.

Mineralys Therapeutics Insider Sold Shares Worth $652,638, According to a Recent SEC Filing

David Malcom Rodman, Chief Medical Officer, on May 11, 2026, sold 22,575 shares in Mineralys Therapeutics (MLYS) for $652,638. Following the Form 4 filing with the SEC, Rodman has control over a total of 63,443 common shares of the company, with 63,443 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1933414/000167265926000027/xslF345X05/wk-form4_1778722925.xml

$MLYS

Research55d ago

TD Cowen Initiates Mineralys Therapeutics at Buy

Mineralys Therapeutics (MLYS) has an average rating of buy and mean price target of $49.38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$MLYS

Track with the FINWIRES app suite

FolioX

Track MLYS in your portfolio

WheelAI

Analyze MLYS options with the wheel strategy

StockInsider

See market sentiment on MLYS